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Purpose/objective. The purpose of this study is to assess the Volumetric Arc Therapy (VMAT) as a competitive technique for
Cranio-Spinal Irradiation (CSI) compared to the conventional 3D Conformal Radiotherapy (3D-CRT) technique.
Materials and methods. Two patients were planned for CSI with both 3D-CRT and RapidArc® (Varian Medical Systems VMAT
solution). Both patients were treated in the prone position. Plans were generated using Varian Eclipse Treatment Planning System
(TPS) and delivered by a Varian Clinac DHX with MLC120 and on-board imager for daily on-line image guidance. Dosimetric
veriﬁcation was performed with PTW Octavius and Sun Nuclear ArcCheck phantoms.
Results. The RapidArc® CSI plans were able to achieve similar or improved OAR sparing when compared to 3D-CRT. RapidArc®
plans were able to decrease the maximum dose to all of the relevant OARs. However, for lungs and bowel, the mean doses were
elevated due to the increased number of beam angles. Also RapidArc® plans resulted in a better dose coverage and homogeneity
in the target volume. A possible 3mm shift had only a minor effect on the dose distribution of the RapidArc® treatment whereas
with the 3D-CRT the shift would result in an unacceptable error (30–40%) of the calculated dose.
Conclusions. The dosimetric results indicate that RapidArc® is an advantageous alternative for CSI. The “low dose bath effect”
remains a controversial issue in all IMRT treatments, especially in the paediatric population. With the RapidArc® technique only
a treatment plan is required to deliver the total treatment dose, eliminating the need for ﬁeld matching techniques. Moreover,
the resulting dose distribution is also less volatile for technical uncertainties of the treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.126
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Introduction. Glioblastoma (GB) is the most common and malignant brain tumour in adults. Extensive surgical resection followed
by radio-chemotherapy is the current standard treatment. When biopsy is the only surgical procedure the prognostic is worse.
Age and KPS (Karnofsky Performance Status) are the most important clinical prognostic factors. Elderly patients (>70 years) are
often excluded from trials and their treatment is controversial. The aim of this study is to asses the outcome of GB patients with
biopsy-only surgical procedure and show the differences between patients younger and older than 70 years.
Material and methods. We reviewed 102 of 298 patients (34.2%) treated underwent biopsy in our hospital between January 2000
and December 2011, prospectively included in our date base. There were 58 males (57%). Median age was 60 years and median
KPS 70. Twenty-one elderly patients (20.6%, range: 71–81) and 81 younger patients (79.4%, range: 24–70). Statistical methods: All
calculations were performed by SPSS 18.0 version; p-values of <0.05 was considered signiﬁcant.
Results. Thirty-nine patients (38.2%) received no further treatment after biopsy. The most frequent causes for withholding treat-
ment were a low KPS (92.3% of untreated patients had a KPS<70 (p<0.0001)). Seventeen of the 21 elderly patients had a KPS<70
(80.9%). Furthermore, 52% of elderly patients received no adjuvant treatment (11/21).
Conclusions. 1/3 of patients with GB undergo a biopsy as the only surgical procedure and one out of three patients were not treated
after biopsy, rising to 50% in elderly patients. The main associated factor with no treatment was lower KPS, frequently viewed
in elderly patients (80% of elderly patients had a KPS<70).
http://dx.doi.org/10.1016/j.rpor.2013.03.127
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Purpose. The objective is to evaluate age, survival, time to tumor progression, therapy, and the effect of treatment at the time of
progression in patients with anaplastic astrocytoma, who had been treated with radiotherapy and concomitant temozolamide.
Patients and methods. Between January 2007 and December 2012, 22 patients (12 male, 10 female and median age 49 years) with
highly anaplastic astrocytomas were diagnosed in our hospital. According to any of several protocols, we treated 18 patients with
radiotherapy and concomitant temozolomide. Eleven of them underwent surgery. Three patients were treated with exclusive
radiotherapy with palliative intention. There was a patient who died from cardiovascular disease.
Results. The overall median survival of all patients was projected as 22 months (range 8–68 months). Five patients had a ﬁrst
relapse and the median time to ﬁrst tumor progression was 13 months (range 1–24 months). The median survival time measured
after the ﬁrst progression was 11 months (range 1–24 months). The eleven patients who were operated had a median survival
of 22 months and not operated with RTCT treatment of 13.5 months. Progression-free survival (PFS) at 6 months, the primary
protocol end point, was 100% and PFS at 12 months was 89%. The 6, 12, 24 and 60 months survival rates were 100%, 82.3%, 47%
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and 11.7%, respectively. Age had a signiﬁcant inﬂuence on survival and on time to the ﬁrst tumor progression, whereas extent
of surgery in the initial therapy did not.
Conclusion. We conclude that these patients can expect a median survival of over 2 years and that young age have a positive
inﬂuence on survival, and that salvage therapies can extend survival after the onset of tumor progression for nearly a year.
http://dx.doi.org/10.1016/j.rpor.2013.03.128
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Patients and methods. We have analyzed the clinical course of 49 patients who underwent initial microsurgery tumor resection
and implantation carmustine-containing wafers into the resection cavity. Time period ranged from 2003 to 2012. Forty-nine
were included (18 females and 31 males) with a mean age of 53.3 years. First symptom mots common: motor impairment 49.9%.
Histology was conﬁrmed as glioblastoma in 91.8%, anaplastic astrocytoma, 6.1%. Karnofsky performance status (KPS) was 100
in 73.5%, 90 in 22.4% and 80 in 4.1%. Surgery was reported as gross total resection in 85.7% and parcial resection in 14.3%. 46.2%
of patients were treated using carmustine wafers followed by standard radiotherapy (RT) with concomitant and adjuvant temo-
zolomide (TMZ); 51.3%, carmustine wafers and RT with adjuvant TMZ; 2.6%, carmustine wafers and RT with concomitant TMZ.
45.8% patients do not completed treatment. Reasons for discontinuation were progression (86.4%) and adverse events (13.6%).
Results. After a median follow-up of 84 months, 81.3% progressed and 83.3% died. One, two and three year OS rates were 60.5%,
21.3%, 13.3% respectively, and four, ﬁve, six and seven year rates were 10.7%. Mean OS was 21.83 months (95% CI, 14.9–28.8) and
median OS was 15 months (95% CI, 11.8–18.2). One, two, three year PFS rates were 30.8%, 5.1%, 2.6% respectively, and four, ﬁve,
six and seven year rates were 0%. Mean PFS was 11 months (95% CI, 8.2–13.7) and median PFS was 8 months (95% CI, 4.9–11).
Subgroup analyses for know clinical prognostic factors demonstrated prolonged OS in patients younger than 60 years and who
had KPS 100 and the PFS was signiﬁcant in KPS 100.
Conclusion. The use of carmustine wafers with radiation and concomitant and adjuvant TMZ does not appear to result in new
types of adverse events. A better outcome was seen in patients younger than 60 years and who had KPS 100.
http://dx.doi.org/10.1016/j.rpor.2013.03.129
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Introduction. Craniospinal irradiation is the standard treatment of some central nervous system tumors. The main difﬁculty of
this irradiation arises by the length of the region to be irradiated, which requires the use of several isocenters, with the problem
of the junction ﬁeld, the use of direct ﬁelds and source-surface distance (SSD) differently to standard.
Objective. Description of a radiotherapy planning technique for craniospinal irradiation that eliminates some of the problems of
conventional techniques.
Methods. We place the patient in prone position, with a thermoplastic mask and a vacuum mattress. The treatment planning
includes two or three isocenters (lumbar, thoracic and cervical). Initially lumbar isocenter is positioned at a 100 cm SSD, using
for this zone 3 beams (anteroposterior and 2 oblique). Then the isocenter cervical is positioned and ﬁnally dorsal isocenter by
anteroposterior ﬁeld, with the table and the collimator rotated to 90◦, following the divergence of the lumbar and brain beams.
Finally the brain area is treated by two opposing lateral beams, with collimator rotation. We made a direct treatment planning
by step-and-shoot, optimized by the algorithm of Pinnacle DMPO (own planning process of our Service).
Results. When we compared with standard techniques, less dose is administered in the abdominal area, increasing the dose in
the mouth, but within tolerable limits. The dose-volume histogram (HDV), are similar to the tomotherapy treatments.
Conclusions. Our craniospinal irradiation technique has some advantages of standard treatment and some disadvantages are
improved (dose reduction in risk organs, standard SSD),making it a relatively easy alternative to the completion and improvement
of this treatment.
http://dx.doi.org/10.1016/j.rpor.2013.03.130
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